Some researchers are considering the impact of somatostatin antagonists or agents that suppress somatostatin secretion that could be used along with insulin therapy to restore a more appropriate release of glucagon during hypoglycemia and postprandial or fasting conditions (24). This evidence concerns the gene INS and Hypoglycemia.